Furosemide

• Catalog No.: DB00695
• CAS Number: 54-31-9
• M. F.: C12H11ClN2O5S
• M. W.: 330.74414

SYNONYMS

• IUPAC name: 4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
• IUPAC Traditional name: furosemide
• Brand Name: Discoid; Macasirool; Hydrenox; Diumide-K; Diurolasa; Rusyde; Aisemide; Beronald; Dryptal; Frumex; Lasemid; Lasix Special; Lazix; Nelsix; Novosemide; Rosis; Spirofur; Synephron; Aquasin; Diural; Fluss; Frusemin; Fuluvamine; Furesis; Furomen; Furorese; Furose; Furosix; Furoter; Furovite; Less Diur; Lowpston; Lowpstron; Luscek; Polysquall A; Salinex; Selectofur; Urex-M; Yidoli; Apo-Frusemide; Arasemide; Bioretic; Bristab; Bristurin; Disal; Diuzol; Dranex; Durafurid; Edenol; Farsix; Franyl; Frumide; Frumil; Frusema; Frusid; Fulsix; Furantril; Furetic; Furex; Furo-Basan; Furo-Puren; Furodrix; Furosan; Furosemix; Furosifar; Fursol; Hydro; Hydro-Rapid; Impugan; Jenafusid; Kutrix; Lasilix; Liside; Marsemide; Myrosemide; Nadis; Prefemin; Promedes; Radouna; Rosemide; Sal Diureticum; Salurid; Trofurit; Urian; Aldalix; Aldic; Aluzine; Anfuramaide; Apo-Furosemide; Aquarid; Cetasix; Depix; Desal; Desdemin; Di-Ademil; Dirine; Disemide; Diurapid; Diuretic Salt; Diusemide; Diusil; Edemid; Eliur; Elodrine; Endural; Errolon; Eutensin; Finuret; Fluidrol; Frusedan; Frusenex; Frusetic; Fuluvamide; Furanthril; Furanthryl; Furanturil; Furfan; Furix; Furmid; Furobeta; Furocot; Furodiurol; Furomex; Furomide M.D.; Furosedon; Furoside; Fusid; Golan; Hissuflux; Hydol; Hydrex; Hydroled; Katlex; Kofuzon; Kolkin; Lasiletten; Lasix; Lasix Retard; Leodrine; Logirene; Mirfat; Mita; Moilarorin; Neo-Renal; Octan Draselny; Odemase; Odemex; Olmagran; Profemin; Promide; Protargen; Puresis; Radisemide; Radonna; Retep; Rodiuran; Rontyl; Salix; Salurex; Saluron; Seguril; Sigasalur; Sisuril; Transit; Uremide; Uresix; Urex; Uridon; Uritol; Urosemide; Vergonil; Vesix; Diucardin; Diurin; Lasex; Laxur; Oedemex; Zafimida
• Synonyms: Furosemida [INN-Spanish]; Furosemid; Frusemide; Fursemid; Fursemida; Frusemid; Dihydroflumethiazide; Furosemidu [Polish]; Furosemidum [INN-Latin]; Fursemide; Methforylthiazidine; Metflorylthiazidine

DATABASE IDS

• PubChem SID: 46506779
• CAS Number: 54-31-9
• PubChem CID: 3440

PROPERTIES

• Hydrophobicity(logP): 1.4
• Solubility: 0.006 mg/mL

DETAILS

Description (English)

• Drug Groups: approved
• Description: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for edema and chronic renal insufficiency. [PubChem]
• Indication: For the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Also for the treatment of hypertension alone or in combination with other antihypertensive agents.
• Pharmacology: Furosemide, a sulfonamide-type loop diuretic structurally related to bumetanide, is used to manage hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome.
• Toxicity: Profound diuresis may cause fluid and electrolyte depletion. Excessive dehydration and potassium depletion may occur. Excessive diuresis may cause rapid weight loss, orthostatic hypotension or acute hypotensive episodes. May also cause tinnitus, reversible or permanent hearing loss or reversible deafness.
• Affected Organisms: Humans and other mammals
• Biotransformation: Only a small amount is hepatically metabolized to the defurfurylated derivative, 4-chloro-5-sulfamoylanthranilic acid.
• Absorption: 60% absorbed in patients with normal renal function
• Half Life: 2 hours
• Protein Binding: 95% bound to plasma proteins
• Elimination: Furosemide is excreted in urine. Significantly more furosemide is excreted in urine following the I.V. injection than after the tablet or oral solution.
• References: Rais-Bahrami K, Majd M, Veszelovszky E, Short BL: Use of furosemide and hearing loss in neonatal intensive care survivors. Am J Perinatol. 2004 Aug;21(6):329-32. [Pubmed] ; Korpi ER, Kuner T, Seeburg PH, Luddens H: Selective antagonist for the cerebellar granule cell-specific gamma-aminobutyric acid type A receptor. Mol Pharmacol. 1995 Feb;47(2):283-9. [Pubmed] ; Tia S, Wang JF, Kotchabhakdi N, Vicini S: Developmental changes of inhibitory synaptic currents in cerebellar granule neurons: role of GABA(A) receptor alpha 6 subunit. J Neurosci. 1996 Jun 1;16(11):3630-40. [Pubmed] ; Wafford KA, Thompson SA, Thomas D, Sikela J, Wilcox AS, Whiting PJ: Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit. Mol Pharmacol. 1996 Sep;50(3):670-8. [Pubmed]
• External Links: Wikipedia; RxList; Drugs.com

REFERENCES

• Rais-Bahrami K, Majd M, Veszelovszky E, Short BL: Use of furosemide and hearing loss in neonatal intensive care survivors. Am J Perinatol. 2004 Aug;21(6):329-32. Pubmed
• Korpi ER, Kuner T, Seeburg PH, Luddens H: Selective antagonist for the cerebellar granule cell-specific gamma-aminobutyric acid type A receptor. Mol Pharmacol. 1995 Feb;47(2):283-9. Pubmed
• Tia S, Wang JF, Kotchabhakdi N, Vicini S: Developmental changes of inhibitory synaptic currents in cerebellar granule neurons: role of GABA(A) receptor alpha 6 subunit. J Neurosci. 1996 Jun 1;16(11):3630-40. Pubmed
• Wafford KA, Thompson SA, Thomas D, Sikela J, Wilcox AS, Whiting PJ: Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit. Mol Pharmacol. 1996 Sep;50(3):670-8. Pubmed